UPPSALA, Sweden, Feb. 19, 2020 /PRNewswire/ -- Orexo AB (publ.),
today invites investors, analysts and media to attend the company's
Capital Markets Day, taking place in Stockholm, Sweden, on
March 17, at Helio GT30, Grev
Turegatan 30.
Members of Orexo's management team, including recently appointed
EVP Digital Therapeutics, Dennis
Urbaniak, will provide an update on the company's strategy,
R&D pipeline and business opportunities within digital health.
Also speaking will be Dr. Mario
Weiss, CEO and Founder of GAIA
AG, a global leader in digital therapeutics.
The agenda for the day is displayed below. To register for the
event please use the following link
https://financialhearings.com/event/12588/register/live_event
|
Time pm
CET
|
Topic or
activity
|
Presenter
|
|
1:00 -1:30
|
Registration and
coffee
|
|
|
Part 1 - Growth
Strategy
|
|
1:30 -
1:50
|
Strategy for short-
and long-term growth
|
Nikolaj Sørensen, CEO
and
President
|
|
1:50 -
2:10
|
Growing the Zubsolv®
franchise
|
Robert DeLuca,
President of
Orexo US Inc.
|
|
Part 2 - Pharma
R&D Pipeline
|
|
2:10 -
2:30
|
A pipeline with
significant future potential
|
Johannes Doll, EVP
and
Chief Commercial Officer
|
|
2:30 -
2:35
|
Q&A
session
|
|
|
2:35 -
2:45
|
Break
|
|
|
Part 3 - Digital
Therapeutics (DTx)
|
|
2:45 -
3:10
|
DTx - new frontiers
in patient care
|
Dennis
Urbaniak,
EVP Digital Therapeutics
|
|
3:10 -
3:40
|
GAIA - a global
leader in digital
therapeutics
|
Dr. Mario Weiss, CEO
and founder
of GAIA AG
Nikolaj Sørensen, CEO
and
President
|
|
3:40 -
3:55
|
Q&A
session
|
|
3:55 -
4:00
|
Concluding
remarks
|
|
4:00
|
Mingle and
buffet
|
|
Robert Rönn, VP and Head of R&D, and Mike Sumner, Chief Medical Officer, will attend
the
Q&A sessions.
Minor changes can be done in the agenda ahead of the event.
About Orexo
Orexo develops and commercializes improved pharmaceuticals and
digital therapeutics, addressing unmet medical needs mainly within
the growing space of addiction. Approved products are
commercialized by Orexo in the US or worldwide via partners.
Orexo's main market is the US for buprenorphine/naloxone products,
where Orexo commercializes its lead product Zubsolv®, for the
treatment of opioid use disorder. Total net sales for 2019 amounted
to SEK 844.8 million and the number
of employees was 128. Orexo is listed on the Nasdaq Stockholm Mid
Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The
company is headquartered in Uppsala, Sweden, where research and development
activities are performed.
For more information about Orexo please visit,
www.orexo.com. You can also follow Orexo on Twitter,
@orexoabpubl, LinkedIn and YouTube.
The information was submitted for publication at 8:00 am CET, on February
19, 2020.
For further information, please contact:
Orexo AB (publ.)
Lena Wange
IR and Communications Manager
Tel: +46-(0)18-780-88-00
Email: ir@orexo.com
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/orexo/r/invitation---orexo-capital-markets-day--stockholm--sweden--march-17,c3038855
The following files are available for download:
https://mb.cision.com/Main/694/3038855/1196413.pdf
|
Invitation â€" Orexo
Capital Markets Day, Stockholm, Sweden, March 17
|